邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

炎症反应在冠状动脉微血管疾病中的研究进展

曹俊,  秦晋梅,  薛伟珍

downloadPDF
文章导航 > 协和医学杂志  > 2022 >  13(6): 1057-1063
曹俊, 秦晋梅, 薛伟珍. 炎症反应在冠状动脉微血管疾病中的研究进展[J]. 协和医学杂志, 2022, 13(6): 1057-1063. doi: 10.12290/xhyxzz.2021-0782
引用本文: 曹俊, 秦晋梅, 薛伟珍. 炎症反应在冠状动脉微血管疾病中的研究进展[J]. 协和医学杂志, 2022, 13(6): 1057-1063. doi: 10.12290/xhyxzz.2021-0782
shu
CAO Jun, QIN Jinmei, XUE Weizhen. Recent Advances in the Pathogenesis of Coronary Microvascular Disease: The role of Inflammatory Reactions[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1057-1063. doi: 10.12290/xhyxzz.2021-0782
Citation: CAO Jun, QIN Jinmei, XUE Weizhen. Recent Advances in the Pathogenesis of Coronary Microvascular Disease: The role of Inflammatory Reactions[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1057-1063. doi: 10.12290/xhyxzz.2021-0782
shu

炎症反应在冠状动脉微血管疾病中的研究进展

doi: 10.12290/xhyxzz.2021-0782
  • 1.

    山西医科大学，太原 030000

  • 2.

    山西医科大学附属太原中心医院心血管内科，太原 030001

基金项目: 

山西省卫生健康委科研项目 2017140

详细信息
    通讯作者:

    薛伟珍, E-mail：tyby6387@163.com

  • 中图分类号: R543.3+1

Recent Advances in the Pathogenesis of Coronary Microvascular Disease: The role of Inflammatory Reactions

  • 1.

    Shanxi Medical University, Taiyuan 030000, China

  • 2.

    Department of Cardiology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan 030001, China

Funds: 

Scientific Research Project of Health Commission of Shanxi Province 2017140

More Information

    摘要
  • 摘要: 冠状动脉微血管疾病(coronary microvascular disease，CMVD)是非阻塞性冠状动脉病变患者心肌缺血的主要原因，由于起病隐匿、病因复杂，目前对其病理生理机制尚缺乏全面认识，极大地限制了其临床诊断与治疗。冠状动脉微血管内皮细胞损伤是诱发CMVD的核心，多种炎症因子可通过内皮细胞损伤途径参与CMVD病情进展。本文主要对炎症反应在CMVD中的可能作用机制作一综述，以期为CMVD的诊断、治疗及预防提供参考。
    Abstract: Coronary microvascular disease(CMVD)is the main cause of myocardial ischemia in patients with non-obstructive coronary artery disease. However, there is still a lack of comprehensive understanding of its pathophysiological mechanism due to the hidden pathogenesis and complex etiologies, which greatly restricts its clinical diagnosis and treatment. The injury of coronary artery microvascular endothelial cells is central to the induction of CMVD, and various inflammatory factors can participate in the pathogenesis of CMVD through the endothelial cell injury pathway. This article mainly reviews the possible mechanisms of inflammatory response in CMVD, in the hope of providing reference for the diagnosis, treatment and prevention of CMVD.
    作者贡献：曹俊负责文献查阅、论文撰写与修订；秦晋梅负责论文写作指导、提出修改意见；薛伟珍负责论文审校。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文
    • 参考文献(71)
  • [1] 张运, 陈韵岱, 傅向华, 等. 冠状动脉微血管疾病诊断和治疗的中国专家共识[J]. 中国循环杂志, 2017, 32: 421-430. doi:  10.3969/j.issn.1000-3614.2017.05.003

    Zheng Y, Chen YD, Fu XH, et al. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases[J]. Zhongguo Xunhuan Zazhi, 2017, 32: 421-430. doi:  10.3969/j.issn.1000-3614.2017.05.003
    [2] Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease[J]. JACC Cardiovasc Imaging, 2015, 8: 1445-1453.
    [3] Gehrie ER, Reynolds HR, Chen AY, et al. Characterization and outcomes of women and men with non-ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: Results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative[J]. Am Heart J 2009, 158: 688-694. doi:  10.1016/j.ahj.2009.08.004
    [4] Zhou W, Lee J, Leung ST, et al. Long-Term Prognosis of Patients With Coronary Microvascular Disease Using Stress Perfusion Cardiac Magnetic Resonance[J]. JACC Cardiovasc Imaging, 2021, 14: 602-611. doi:  10.1016/j.jcmg.2020.09.034
    [5] Siasos G, Tsigkou V, Zaromytidou M, et al. Role of local coronary blood flow patterns and shear stress on the development of microvascular and epicardial endothelial dysfunction and coronary plaque[J]. Curr Opin Cardiol, 2018, 33: 638-644. doi:  10.1097/HCO.0000000000000571
    [6] Niccoli G, Scalone G, Lerman A, et al. Coronary microvascular obstruction in acute myocardial infarction[J]. Eur Heart J, 2016, 37: 1024-1033. doi:  10.1093/eurheartj/ehv484
    [7] Del Buono MG, Montone RA, Camilli M, et al. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2021, 78: 1352-1371. doi:  10.1016/j.jacc.2021.07.042
    [8] Masi S, Rizzoni D, Taddei S, et al. Assessment and pathophysiology of microvascular disease: recent progress and clinical implications[J]. Eur Heart J, 2021, 42: 2590-2604. doi:  10.1093/eurheartj/ehaa857
    [9] Gurzau D, Sitar-Taut A, Caloian B, et al. The Role of IL-6 and ET-1 in the Diagnosis of Coronary MicroVascular Disease in Women[J]. J Pers Med, 2021, 11: 965. doi:  10.3390/jpm11100965
    [10] Ovchinnikov AG, Arefieva TI, Potekhina AV, et al. The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction[J]. Acta Naturae, 2020, 12: 40-51. doi:  10.32607/actanaturae.11154
    [11] Ligthart S, Marzi C, Aslibekyan S, et al. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases[J]. Genome Biol, 2016, 17: 255. doi:  10.1186/s13059-016-1119-5
    [12] Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation[J]. J Am Coll Cardiol, 2013, 62: 263-271. doi:  10.1016/j.jacc.2013.02.092
    [13] Furman D, Campisi J, Verdin E, et al. Chronic inflamma-tion in the etiology of disease across the life span[J]. Nat Med, 2019, 25: 1822-1832. doi:  10.1038/s41591-019-0675-0
    [14] Chae WR, Nübel J, Baumert J, et al. Association of depression and obesity with C-reactive protein in Germany: A large nationally representative study[J]. Brain Behav Immun, 2022, 103: 223-231. doi:  10.1016/j.bbi.2022.04.024
    [15] Recio-Mayoral A, Rimoldi OE, Camici PG, et al. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease[J]. JACC Cardiovasc Imaging, 2013, 6: 660-667. doi:  10.1016/j.jcmg.2012.12.011
    [16] Bajaj NS, Osborne MT, Gupta A, et al. Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients[J]. J Am Coll Cardiol, 2018, 72: 707-717. doi:  10.1016/j.jacc.2018.05.049
    [17] Selthofer-Relatić K, Bošnjak I, Kibel A, et al. Obesity Related Coronary Microvascular Dysfunction: From Basic to Clinical Practice[J]. Cardiol Res Pract, 2016, 2016: 8173816.
    [18] Wang GR, Zhu Y, Halushka PV, et al. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase[J]. Proc Natl Acad Sci U S A, 1998, 95: 4888-4893. doi:  10.1073/pnas.95.9.4888
    [19] Wenzl FA, Ambrosini S, Mohammed SA. Inflammation in Metabolic Cardiomyopathy[J]. Front Cardiovasc Med, 2021, 8: 742178. doi:  10.3389/fcvm.2021.742178
    [20] Tong DC, Whitbourn R, MacIsaac A, et al. High-Sensitivity C-Reactive Protein Is a Predictor of Coronary Microvascular Dysfunction in Patients with Ischemic Heart Disease[J]. Front Cardiovasc Med, 2017, 4: 81.
    [21] Aryan Z, Ghajar A, Faghihi-Kashani S, et al. Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study[J]. Ann Nutr Metab, 2018, 72: 287-295. doi:  10.1159/000488537
    [22] Candela J, Wang R, White C. Microvascular Endothelial Dysfunction in Obesity Is Driven by Macrophage-Dependent Hydrogen Sulfide Depletion[J]. Arterioscler Thromb Vasc Biol, 2017, 37: 889-899. doi:  10.1161/ATVBAHA.117.309138
    [23] Tracy EP, Hughes W, Beare JE, et al. Aging-Induced Impairment of Vascular Function: Mitochondrial Redox Contributions and Physiological/Clinical Implications[J]. Antioxid Redox Signal, 2021, 35: 974-1015. doi:  10.1089/ars.2021.0031
    [24] Barkaway A, Rolas L, Joulia R, et al. Age-related changes in the local milieu of inflamed tissues cause aberrant neutrophil trafficking and subsequent remote organ damage[J]. Immunity, 2021, 54: 1494-1510. doi:  10.1016/j.immuni.2021.04.025
    [25] Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system[J]. Nat Immunol, 2018, 19: 1146.
    [26] Rowe G, Tracy E, Beare JE, et al. Cell therapy rescues aging-induced beta-1 adrenergic receptor and GRK2 dysfunc-tion in the coronary microcirculation[J]. Geroscience, 2021, 44: 329-348.
    [27] Manini TM, Anton SD, Beavers DP, et al. ENabling Reduction of Low-grade Inflammation in SEniors Pilot Study: Concept, Rationale, and Design[J]. J Am Geriatr Soc, 2017, 65: 1961-1968. doi:  10.1111/jgs.14965
    [28] Arora R, Van Theemsche KM, Van Remoortel S, et al. Constitutive, Basal, and β-Alanine-Mediated Activation of the Human Mas-Related G Protein-Coupled Receptor D Induces Release of the Inflammatory Cytokine IL-6 and Is Dependent on NF-κB Signaling[J]. Int J Mol Sci, 2021, 22: 13254. doi:  10.3390/ijms222413254
    [29] Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance[J]. Biochim Biophys Acta, 2015, 1851: 469-484. doi:  10.1016/j.bbalip.2014.08.010
    [30] Teissier T, Boulanger E, Cox LS. Interconnections between Inflammageing and Immunosenescence during Ageing[J]. Cells, 2022, 11: 359. doi:  10.3390/cells11030359
    [31] Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies[J]. Nature, 2020, 583: 127-132. doi:  10.1038/s41586-020-2403-9
    [32] Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging[J]. Cell, 2017, 169: 132-147. doi:  10.1016/j.cell.2017.02.031
    [33] Muñoz-Espín D, Rovira M, Galiana I, et al. A versatile drug delivery system targeting senescent cells[J]. EMBO Mol Med, 2018, 10: e9355.
    [34] Konst RE, Guzik TJ, Kaski JC, et al. The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions[J]. Cardiovasc Res, 2020, 116: 817-828. doi:  10.1093/cvr/cvaa009
    [35] Kuwahata S, Hamasaki S, Ishida S, et al. Effect of uric acid on coronary microvascular endothelial function in women: association with eGFR and ADMA[J]. J Atheroscler Thromb, 2010, 17: 259-269. doi:  10.5551/jat.1594
    [36] Prasad M, Matteson EL, Herrmann J, et al. Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women[J]. Hypertension, 2017, 69: 236-242. doi:  10.1161/HYPERTENSIONAHA.116.08436
    [37] Kakuta K, Dohi K, Yamamoto T, et al. Coronary Microvascular Dysfunction Restored After Surgery in Inflammatory Bowel Disease: A Prospective Observational Study[J]. J Am Heart Assoc, 2021, 10: e19125.
    [38] Plazak W, Gryga K, Milewski M, et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus[J]. Lupus, 2011, 20: 936-944. doi:  10.1177/0961203311399607
    [39] Weber B, Stevens E, Barrett L. Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus[J]. J Am Heart Assoc, 2021, 10: e018555. doi:  10.1161/JAHA.120.018555
    [40] Shin JI, Lee KH, Joo YH, et al. Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review[J]. J Autoimmun, 2019, 103: 102299. doi:  10.1016/j.jaut.2019.06.010
    [41] Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell, 2002, 10: 417-426. doi:  10.1016/S1097-2765(02)00599-3
    [42] Zanatta E, Colombo C, D'Amico G, et al. Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheu-matic Diseases[J]. Int J Mol Sci, 2019, 20: 5563. doi:  10.3390/ijms20225563
    [43] He M, Liang X, He L, et al. Endothelial dysfunction in rheumatoid arthritis: the role of monocyte chemotactic protein-1-induced protein[J]. Arterioscler Thromb Vasc Biol, 2013, 33: 1384-1391. doi:  10.1161/ATVBAHA.113.301490
    [44] Zhang H, Yang K, Chen F, et al. Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications[J]. Front Immunol, 2022, 13: 975367. doi:  10.3389/fimmu.2022.975367
    [45] Jin Z, Zheng E, Sareli C, et al. Monocyte Chemotactic Protein-Induced Protein 1 (MCPIP-1): A Key Player of Host Defense and Immune Regulation[J]. Front Immunol, 2021, 12: 727861. doi:  10.3389/fimmu.2021.727861
    [46] Piaserico S, Osto E, Famoso G, et al. Long-term prognostic value of coronary flow reserve in psoriasis patients[J]. Atherosclerosis, 2019, 289: 57-63. doi:  10.1016/j.atherosclerosis.2019.08.009
    [47] Weber B, Perez-Chada LM, Divakaran S, et al. Coronary microvascular dysfunction in patients with psoriasis[J]. J Nucl Cardiol, 2020, 29: 37-42.
    [48] Garshick MS, Barrett TJ, Wechter T, et al. Inflammasome Signaling and Impaired Vascular Health in Psoriasis[J]. Arterioscler Thromb Vasc Biol, 2019, 39: 787-798. doi:  10.1161/ATVBAHA.118.312246
    [49] Piaserico S, Osto E, Famoso G, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis[J]. Atherosclerosis, 2016, 251: 25-30. doi:  10.1016/j.atherosclerosis.2016.05.036
    [50] Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis[J]. J Am Acad Dermatol, 2018, 79: 345-352. doi:  10.1016/j.jaad.2018.02.040
    [51] Guo J, Wei X, Li Q, et al. Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury[J]. J Cell Physiol, 2020, 235: 9884-9894. doi:  10.1002/jcp.29802
    [52] Rasmi Y, Rouhrazi H, Khayati-Shal E, et al. Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in patients with cardiac syndrome X[J]. Biomed J, 2016, 39: 339-345. doi:  10.1016/j.bj.2016.01.010
    [53] Temesgen GB, Menon M, Gizaw ST, et al. Evaluation of Lipid Profile and Inflammatory Marker in Patients with Gastric Helicobacter pylori Infection, Ethiopia[J]. Int J Gen Med, 2022, 15: 271-278. doi:  10.2147/IJGM.S345649
    [54] Zhang DH, Yuan C, Wang BB, et al. Helicobacter pylori Infection Maybe a Risk Factor for Cardiac Syndrome X[J]. Front Cardiovasc Med, 2022, 9: 823885. doi:  10.3389/fcvm.2022.823885
    [55] Tanaka T, Matsushita M, Oka Y, et al. Effect of Chlamydia pneumoniae infection on coronary flow reserve and intimal hyperplasia after stent implantation in patients with angina pectoris[J]. Cardiol, 2001, 38: 311.
    [56] Liuba P, Pesonen E, Paakkari I, et al. Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs[J]. Atherosclerosis, 2003, 167: 215-222. doi:  10.1016/S0021-9150(03)00019-4
    [57] Almeida NC, Queiroz MA, Lima SS, et al. Association of Chlamydia trachomatis, C. pneumoniae, and IL-6 and IL-8 Gene Alterations With Heart Diseases[J]. Front Immunol, 2019, 10: 87. doi:  10.3389/fimmu.2019.00087
    [58] Wagner J, Bojkova D, Shumliakivska M, et al. Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants[J]. Basic Res Cardiol, 2021, 116: 42. doi:  10.1007/s00395-021-00882-8
    [59] Yin J, Wang S, Liu Y, et al. Coronary microvascular dys function pathophysiology in COVID-19[J]. Microcirculation, 2021, 28: e12718.
    [60] Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis[J]. Clin Chim Acta, 2020, 507: 167-173. doi:  10.1016/j.cca.2020.04.027
    [61] Cenko E, Badimon L, Bugiardini R, et al. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)[J]. Cardiovasc Res, 2021, 117: 2705-2729. doi:  10.1093/cvr/cvab298
    [62] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395: 1417-1418 doi:  10.1016/S0140-6736(20)30937-5
    [63] Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options[J]. Cardiovasc Res, 2020, 116: 1666-1687. doi:  10.1093/cvr/cvaa106
    [64] Rethy L, Feinstein MJ, Sinha A, et al. Coronary Microvascular Dysfunction in HIV: A Review[J]. J Am Heart Assoc, 2020, 9: e14018.
    [65] Kristoffersen US, Wiinberg N, Petersen CL, et al. Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation[J]. Nucl Med Commun, 2010, 31: 874-880. doi:  10.1097/MNM.0b013e32833d82e6
    [66] Knudsen A, Thorsteinsson K, Christensen TE, et al. Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G[J]. Open Forum Infec Dis, 2018, 5: ofy205. doi:  10.1093/ofid/ofy205
    [67] Leucker TM, Weiss RG, Schär M, et al. Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol[J]. J Am Heart Assoc, 2018, 7: e9996.
    [68] Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV[J]. Curr HIV/AIDS Rep, 2017, 14: 93-100. doi:  10.1007/s11904-017-0356-x
    [69] 靳刚强. 尼可地尔治疗微血管性心绞痛的疗效及其对血管内皮功能的影响[J]. 当代医学, 2016, 22: 131-132. https://www.cnki.com.cn/Article/CJFDTOTAL-DDYI201623091.htm

    Jin GQ. Effect of nicorandil on microvascular angina pectoris and its effect on vascular endothelial function[J]. Dangdai Yixue, 2016, 22: 131-132. https://www.cnki.com.cn/Article/CJFDTOTAL-DDYI201623091.htm
    [70] Luo WH, Guo Y, Huang JW, et al. Do Statins Have a Positive Impact on Patients with Coronary Microvascular Dysfunction on Long-Term Clinical Outcome? A Large Retrospective Cohort Study[J]. Biomed Res Int, 2019, 2019: 4069097.
    [71] Juni RP, Kuster DW, Goebel MM, et al. Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin[J]. JACC Basic Transl Sci, 2019, 4: 575-591. doi:  10.1016/j.jacbts.2019.04.003
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  218
  • HTML全文浏览量:  37
  • PDF下载量:  48
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-10
  • 录用日期:  2022-01-11
  • 网络出版日期:  2022-11-07
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！